I Tinhofer1, V Budach2, M Saki2, R Konschak2, F Niehr2, K Jöhrens3, W Weichert4, A Linge5, F Lohaus5, M Krause6, K Neumann7, V Endris8, A Sak9, M Stuschke9, P Balermpas10, C Rödel10, M Avlar11, A L Grosu11, A Abdollahi12, J Debus12, C Belka13, S Pigorsch14, S E Combs15, D Mönnich16, D Zips16, M Baumann6. 1. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites, Berlin, Germany; Department of Radiooncology and Radiotherapy, Charité University Hospital Berlin, Germany. Electronic address: ingeborg.tinhofer@charite.de. 2. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites, Berlin, Germany; Department of Radiooncology and Radiotherapy, Charité University Hospital Berlin, Germany. 3. Institute of Pathology, Charité-University Hospital Berlin, Germany. 4. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites, Munich, Germany; Institute of Pathology, University Hospital Heidelberg and National Center for Tumor Disease, Germany; Institute of Pathology, Technical University Munich, Germany. 5. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites, Dresden, Germany; Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology (NCRO), Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany. 6. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites, Dresden, Germany; Department of Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology (NCRO), Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; Helmholtz-Zentrum Dresden, Rossendorf, Dresden, Germany. 7. Institute of Biometry and Clinical Epidemiology, Charité University Hospital Berlin, Germany. 8. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites, Munich, Germany; Institute of Pathology, University Hospital Heidelberg and National Center for Tumor Disease, Germany. 9. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites, Essen, Germany; Department of Radiotherapy, Medical Faculty, University of Duisburg-Essen, Essen, Germany. 10. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites, Frankfurt, Germany; Department of Radiotherapy and Oncology, Goethe-University Frankfurt, Germany. 11. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites, Freiburg, Germany; Department of Radiation Oncology, University of Freiburg, Germany. 12. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites, Heidelberg, Germany; Department of Radiation Oncology, Heidelberg Ion Therapy Center (HIT), Heidelberg Institute of Radiation Oncology (HIRO) and National Center for Radiation Research in Oncology (NCRO), Germany. 13. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites, Munich, Germany; Department of Radiotherapy and Radiation Oncology, Ludwig-Maximilians-Universität, Munich, Germany. 14. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites, Munich, Germany; Department of Radiation Oncology, Technical University Munich, Germany. 15. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites, Munich, Germany; Department of Radiation Oncology, Technical University Munich, Germany; Institute of Innovative Radiotherapy, Helmholtz Center Munich, Germany. 16. German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK) partner sites, Tübingen; Germany; Department of Radiation Oncology, Faculty of Medicine and University Hospital Tübingen, Eberhard Karls Universität Tübingen, Germany.
Abstract
BACKGROUND: Despite clear differences in clinical presentation and outcome, squamous cell carcinomas of the head and neck (SCCHN) arising from human papilloma virus (HPV) infection or heavy tobacco/alcohol consumption are treated equally. Next-generation sequencing is expected to reveal novel targets for more individualised treatment. PATIENTS AND METHODS: Tumour specimens from 208 patients with locally advanced squamous cell carcinoma of the hypopharynx, oropharynx or oral cavity, all uniformly treated with adjuvant cisplatin-based chemoradiation, were included. A customised panel covering 211 exons from 45 genes frequently altered in SCCHN was used for detection of non-synonymous point and frameshift mutations. Mutations were correlated with HPV status and treatment outcome. RESULTS: Mutational profiles and HPV status were successfully established for 179 cases. HPV- tumours showed an increased frequency of alterations in tumour suppressor genes compared to HPV+ cases (TP53 67% versus 4%, CDKN2A 18% versus 0%). Conversely, HPV+ carcinomas were enriched for activating mutations in driver genes compared to HPV- cases (PIK3CA 30% versus 12%, KRAS 6% versus 1%, and NRAS 4% versus 0%). Hotspot TP53 missense mutations in HPV- carcinomas correlated with an increased risk of locoregional recurrence (hazard ratio [HR] 4.3, 95% confidence interval [CI] 1.5-12.1, P=0.006) and death (HR 2.2, 95% CI 1.1-4.4, P=0.021). In HPV+ SCCHN, driver gene mutations were associated per trend with a higher risk of death (HR 3.9, 95% CI 0.7-21.1, P=0.11). CONCLUSIONS: Distinct mutation profiles in HPV- and HPV+ SCCHN identify subgroups with poor outcome after adjuvant chemoradiation. Mutant p53 and the phosphoinositide 3-kinase pathway were identified as potential druggable targets for subgroup-specific treatment optimisation.
BACKGROUND: Despite clear differences in clinical presentation and outcome, squamous cell carcinomas of the head and neck (SCCHN) arising from human papilloma virus (HPV) infection or heavy tobacco/alcohol consumption are treated equally. Next-generation sequencing is expected to reveal novel targets for more individualised treatment. PATIENTS AND METHODS: Tumour specimens from 208 patients with locally advanced squamous cell carcinoma of the hypopharynx, oropharynx or oral cavity, all uniformly treated with adjuvant cisplatin-based chemoradiation, were included. A customised panel covering 211 exons from 45 genes frequently altered in SCCHN was used for detection of non-synonymous point and frameshift mutations. Mutations were correlated with HPV status and treatment outcome. RESULTS: Mutational profiles and HPV status were successfully established for 179 cases. HPV- tumours showed an increased frequency of alterations in tumour suppressor genes compared to HPV+ cases (TP53 67% versus 4%, CDKN2A 18% versus 0%). Conversely, HPV+ carcinomas were enriched for activating mutations in driver genes compared to HPV- cases (PIK3CA 30% versus 12%, KRAS 6% versus 1%, and NRAS 4% versus 0%). Hotspot TP53 missense mutations in HPV- carcinomas correlated with an increased risk of locoregional recurrence (hazard ratio [HR] 4.3, 95% confidence interval [CI] 1.5-12.1, P=0.006) and death (HR 2.2, 95% CI 1.1-4.4, P=0.021). In HPV+ SCCHN, driver gene mutations were associated per trend with a higher risk of death (HR 3.9, 95% CI 0.7-21.1, P=0.11). CONCLUSIONS: Distinct mutation profiles in HPV- and HPV+ SCCHN identify subgroups with poor outcome after adjuvant chemoradiation. Mutant p53 and the phosphoinositide 3-kinase pathway were identified as potential druggable targets for subgroup-specific treatment optimisation.
Authors: Stefan Holzhauser; Ourania N Kostopoulou; Anna Ohmayer; Birthe K A Lange; Torbjörn Ramqvist; Teodora Andonova; Cinzia Bersani; Malin Wickström; Tina Dalianis Journal: Oncol Lett Date: 2019-10-09 Impact factor: 2.967
Authors: Thomas C Westbrook; Ian S Hagemann; Jessica Ley; Kevin Chen; Kevin Palka; Jingxia Liu; Ling Chen; Peter Oppelt; Douglas Adkins Journal: Med Oncol Date: 2019-12-21 Impact factor: 3.064
Authors: Cinzia Bersani; Lars Sivars; Linnea Haeggblom; Sebastian DiLorenzo; Michael Mints; Andreas Ährlund-Richter; Nikolaos Tertipis; Eva Munck-Wikland; Anders Näsman; Torbjörn Ramqvist; Tina Dalianis Journal: Oncotarget Date: 2017-05-23
Authors: Rick Kamps; Rita D Brandão; Bianca J van den Bosch; Aimee D C Paulussen; Sofia Xanthoulea; Marinus J Blok; Andrea Romano Journal: Int J Mol Sci Date: 2017-01-31 Impact factor: 5.923
Authors: Stefan Holzhauser; Nicole Wild; Mark Zupancic; Ramona G Ursu; Cinzia Bersani; Anders Näsman; Ourania N Kostopoulou; Tina Dalianis Journal: Front Oncol Date: 2021-05-11 Impact factor: 6.244